Targeting WEE1 Kinase for Breast Cancer Therapeutics: An Update
Just a mention. But confirmation that in the metastatic setting ICI is no more effective than chemo. I think. Maybe posted before
https://pmc.ncbi.nlm.nih.gov/articles/PMC12192920/
.."The immune checkpoint inhibitor pembrolizumab was approved by the FDA for early-stage TNBC based on the results of a clinical trial (KEYNOTE-522) demonstrating improved pathological complete response (pCR) and event-free survival (EFS) rates in patients receiving pembrolizumab compared to those receiving a placebo [48].
..." In the metastatic pretreated setting, pembrolizumab did not show a survival advantage over chemotherapy"...
...Sacituzumab govitecan showed improved progression-free and overall survival when compared with single-agent chemotherapy among patients with metastatic triple-negative breast cancer, although grade 3 or higher side effects (myelosuppression (~50%) and diarrhea (10%)) were frequent. A similar prevalence of adverse events was confirmed in a recent real-world study [52]. Although there were no complete responses amongst the 149 patients, progression-free survival was 5.7 months [52].
.." Interestingly, treatment with a humanized monoclonal antibody to CCR5 (leronlimab) used in a pooled analysis of pretreated metastatic TNBC patients showed no grade three toxicities related to therapy and a 3 year survival of 19.8% [53,54]. Overall, 88% of patients who received a dose of 525 or 700 mg showed an upregulation of PD-L1 in circulating tumor cells. Patients who showed a significant induction of PD-L1 on their CTC with leronlimab, and received an immune check point inhibitor, were alive (>48 months)"...
Just a mention. But confirmation that in the metastatic setting ICI is no more effective than chemo. I think. Maybe posted before
https://pmc.ncbi.nlm.nih.gov/articles/PMC12192920/
.."The immune checkpoint inhibitor pembrolizumab was approved by the FDA for early-stage TNBC based on the results of a clinical trial (KEYNOTE-522) demonstrating improved pathological complete response (pCR) and event-free survival (EFS) rates in patients receiving pembrolizumab compared to those receiving a placebo [48].
..." In the metastatic pretreated setting, pembrolizumab did not show a survival advantage over chemotherapy"...
...Sacituzumab govitecan showed improved progression-free and overall survival when compared with single-agent chemotherapy among patients with metastatic triple-negative breast cancer, although grade 3 or higher side effects (myelosuppression (~50%) and diarrhea (10%)) were frequent. A similar prevalence of adverse events was confirmed in a recent real-world study [52]. Although there were no complete responses amongst the 149 patients, progression-free survival was 5.7 months [52].
.." Interestingly, treatment with a humanized monoclonal antibody to CCR5 (leronlimab) used in a pooled analysis of pretreated metastatic TNBC patients showed no grade three toxicities related to therapy and a 3 year survival of 19.8% [53,54]. Overall, 88% of patients who received a dose of 525 or 700 mg showed an upregulation of PD-L1 in circulating tumor cells. Patients who showed a significant induction of PD-L1 on their CTC with leronlimab, and received an immune check point inhibitor, were alive (>48 months)"...
18
